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Abstract A goal of testing for latent tuberculosis (TB)
infection is to identify individuals who are at increased risk
for the development of active TB. No laboratory tool is
currently available to distinguish between individuals in
the process of progressing from latent TB infection towards
active disease and those who are not. Determination of the
interferon-gamma and interleukin-2 T cell signature might
provide an additional and rapid tool to evaluate treatment
necessity and clinical management of a patient. Here, we
present three cases of interferon-gamma release assay-
positive patients with differing interferon-gamma and
interleukin-2 signatures when analyzed by the Fluorospot
assay.
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Introduction
The latent state of infection with Mycobacterium tubercu-
losis [latent tuberculosis infection (LTBI)] is probably
maintained by an active immune response in the host ini-
tiated by M. tuberculosis which results in host-controlled
persistence of the organism. LTBI can progress to active
TB disease a long time after the initial infection [1].
Infection with M. tuberculosis manifests as a spectrum of
clinical presentations, including those patients who will
progress to active disease, those who maintain persistent,
lifelong infection but do not progress to active disease,
those who temporarily suppress infection but later develop
active disease, and those who are able to effectively clear
the pathogen.
In countries with a low incidence of TB, targeted testing
for LTBI among risk groups is an important approach to
prevent active TB disease [2]. In most developed countries,
the diagnosis of LTBI increasingly relies on the results of
two ex vivo interferon-gamma (IFN-c) release assays
(IGRA), namely, the QuantiFERON-TB Gold In-Tube
assay (QFT; Qiagen AG, Hombrechtikon, Switzerland) and
the T-SPOT.TB assay (Oxford Immunotec, Oxford, UK)
[3]. These routine laboratory tests utilize specific M.
tuberculosis antigens [T-SPOT.TB assay: early secretory
antigen target-6 (ESAT-6) and culture filtrate protein-10
(CFP-10); QTF (TB7.7) assay: ESAT-6, CFP-10, and
Rv2654c] that are absent from Bacillus Calmette–Gue´rin
(BCG) vaccine and most non-tuberculous mycobacteria to
stimulate IFN-c release. As such, these tests significantly
minimize the number of wrongly diagnosed LTBI cases
due to unknown vaccination status compared to the
tuberculin skin test (TST) [3, 4]. However, the questions of
whether IGRAs can differentiate between persons who will
develop active TB disease and those who will not, and if so
by which mechanism, remain unanswered. There is cur-
rently no laboratory tool available to directly detect indi-
viduals in the process of progressing from LTBI towards
active TB disease. In their recent meta-analysis, Diel and
colleagues showed that the pooled positive predictive value
(PPV) for progression to active TB disease using
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commercial IGRAs was 2.7 % in the included studies and
that the PPV increased to 6.8 % when only high-risk
groups were considered [5]. These authors reported that the
pooled value of the negative predictive value for progres-
sion to active TB disease was very high—99.7 %.
Identifying individuals who are at an elevated risk of
reactivation and/or progression to active TB would aid
clinical management decisions, as M. tuberculosis therapy
is lengthy and adverse effects are not uncommon. In this
context, cytokine profiling is a promising tool [6]. IFN-c/
interleukin-2 (IL-2) profiling identifies T-cell cytokine
signatures which reflect their memory phenotype and
defines functional T-cell subsets, namely, effector cells that
mainly secrete IFN-c only and long-lived central-memory
T-cells secreting only IL-2. Antigen clearance is typically
associated with dominant IL-2 functional T-cell signatures
while, in contrast, high antigen loads are associated with
dominant IFN-c functional T-cell signatures. A dynamic
relationship has been demonstrated in intracellular infec-
tions between antigen load and distinct IFN-c and IL-2
profiles of antigen-specific CD4? T-cells [7]. In the con-
text of M. tuberculosis infection, a study by Millington and
colleagues [8] examined samples from active TB patients
both pre- and post-initiation of treatment. These authors
showed a significant decline in the frequency of ESAT-6/
CFP-10-specific T-cells secreting IFN-c over 28 months
and a significant increase in the number of ESAT-6/CFP-
10-specific T-cells secreting IL-2 during the 6 months of
treatment [8]. In another study, Casey and colleagues [9]
compared patients with active TB and those with LTBI and
found that the latter had a significantly lower proportion of
ESAT-6/CFP-10-specific IFN-c-only-secreting T-cells and
a significantly higher proportion of ESAT-6/CFP-10-spe-
cific dual IFN-c/IL-2-secreting and IL-2-only-secreting
T-cells.
Here we present three cases of persons with positive
IGRA results (QFT- and T-SPOT.TB-positive) who were
putatively infected with M. tuberculosis, with markedly
different single-cell IFN-c and IL-2 signatures when
measured using the Fluorospot assay described in the fol-
lowing section (Figs. 1, 2). When used in a diagnostic
laboratory environment the IFN-c/IL-2 Fluorospot assay
produces low-cost single-cell cytokine profiles for IFN-c
and IL-2. These results provide useful information for
optimizing clinical management of potentially infected
patients. Compared to the previously described enzyme-
linked immunosorbent assay (ELISA) method of determi-
nation of IFN-c and IL-2 using plasma supernatant of
QuantiFERON-TB Gold (QFT ; Qiagen, Hilden, Ger-
many), the Fluorospot assay has the advantage of not being
restricted to the linear range of the ELISA readout and the
usability for immunosuppressed patients since peripheral
blood mononucleated cells (PBMCs) are collected
independently. Additionally, cells secreting both IFN-c and
IL-2 simultaneously can be distinguished from mono-
secreting cells [9, 10].
Methods
The QFT and T-SPOT.TB assays were performed accord-
ing to the respective manufacturer’s instructions. Spot-
forming cells (SFCs) were counted using an AiD-iSpot
reader (Autoimmun Diagnostika GmbH, Strassberg, Ger-
many). PBMCs were collected using Becton–Dickinson
Vacutainer Cell Preparation Tubes (BD BioSciences, San
Jose, CA) following centrifugation for 20 min at room
temperature (RT)/1,650 g (Haereus Megafuge 1.0R;
Thermo Scientific, Waltham, MA). The plasma supernatant
was discarded and the cells were washed twice with 15 ml
10 % phosphate buffered saline and centrifuged for 15 min
at RT/300 g (Haereus Megafuge 1.0R). The cells were then
collected and re-suspended in AIM-V media, a fully-
defined serum-free tissue culture media for immunological
studies [AIM V Medium, liquid (research grade); Albu-
MAX Supplement; Life Technologies, Carlsbad, CA],
counted using a Cell-Dyn Emerald flow-cytometer (Abbott
AG, Liestal, Switzerland), and adjusted to 250,000 PBMC/
100 ll.
The IFN-c/IL-2-Fluorospot assay was performed as
follows: 250,000 PBMCs (100 ll), including anti-CD28
monoclonal antibody (mAb) and a co-stimulatory anti-
CD28 immunoglobulin G (IgG) antibody to counterbalance
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Fig. 1 Three cases of persons with positive interferon-gamma (IFN-
c) release assay (IGRA) results. Patient 1: 62-year-old female; strong
positive IGRA QFT and T-SPOT.TB results; Fluorospot INF-c
dominant signature. Patient 2: 31-year-old female; strong positive
IGRA QFT and T-SPOT.TB results; Fluorospot IFN-c/IL-2 mixed
signature. Patient 3: 55-year-old male; weak positive IGRA QFT and
T-SPOT.TB results; Fluorospot IL-2 dominant signature. QFT was
considered to be positive at [0.35 IU/ml, the T-SPOT.TB was
considered to be positive at [7 spot-forming cells (SFC). Asterisks
For stimulation, the pooled antigen mixture mycobact.tub.filtrate1
(Autoimmun Diagnostika GmbH) was used for the Fluorospot assay.
The different assays used (IGRA QFT, T-SPOT.TB, Fluorospot IL-2)
are described in full in the text. IL-2 Interleukin-2, FITC fluorescein
isothiocyanate
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sequestering of IL-2 by membrane-bound anti-IL-2 capture
antibodies [11] (Anti-Human CD28 mAb CD28-A, 0.1 lg/
ml; MABTECH AB, Nacka Strand, Sweden), were seeded
to each well of an IFN-c/IL-2 capture pre-coated PVDF
membrane plate (MABTECH AB). For each patient, each
well contained plain AIM-V (negative control; Fig. 2,
columns A and D), pokeweed mitogen (Autoimmun Di-
agnostika GmbH, GER) (positive control; Fig. 2, columns
B and E), and 100 ll of the M. tuberculosis antigen mix-
ture mycobact.tub.filtrate1 (Autoimmun Diagnostika
GmbH) (Fig. 2; columns C and F). The plates were incu-
bated at 37 C with 5 % CO2 for 20–24 h, then washed and
incubated at room temperature for another 2 h with FITC-
conjugated anti-IFN-c (7-B6-1-FS-FITC; MABTECH AB;
diluted according to the manufacturer’s instructions) and
0.5 lg/ml biotinylated anti-IL-2 (IL2-II-biotin; MAB-
TECH AB) detection mAbs. The plates were then washed
again and incubated at room temperature for 1 h with
fluorophore-labeled monoclonal anti-FITC-Green antibody
and streptavidin-red (MABTECH AB Fluorospot kit; 1 lg/
ml/Streptavidin-PF555 and anti-FITC-PF488P, PromoCell
GmbH, Heidelberg, Germany). After washing, the plates
were incubated at room temperature for 15 min with
100 ll/well of fluorescence enhancer (MABTECH AB)
before being emptied and air-dried in the dark. SFCs were
counted using an automated AiD-iSpot reader system to
detect PF488P and PF555 fluorophores (ERLIFL05; Au-
toimmun Diagnostika GmbH). The automatic readouts
were validated by visual inspection of the spots by at least
two different persons.
Results
Patient 1 was a 62-year-old female of Swiss descent, in
good general condition, health care worker (HCW). The
infection was identified via a hospital active TB contact
screening program (no prolonged contact with the infected
patient). The clinical history revealed a period of prolonged
coughing as a child, a positive TST test ([20 mm) of
unknown date, and a link between the coughing and an
unknown BCG-vaccination status. No abnormalities were
detected on the chest X-ray. Both IGRA tests were clearly
positive: the QFT result was 6.38 IU/ml and the
T-SPOT.TB results of 26 spots for ESAT-6 and 53 spots for
CFP-10, respectively. In clinical terms the positive IGRAs
were interpreted as indicating a historical contact with M.
tuberculosis during adolescence. Even though the recent
exposure may not have resulted in infection, in this case a
previous infection might be progressing to active disease
(i.e., re-activation), and this transition stage was only
detected by chance. The patient refused preventive
Fig. 2 Three cases of IGRA-positive patients with different IFN-c
and IL-2 signatures by the Fluorospot assay. 1A–1F Patient 1 (62-
year-old female), IFN-c dominant signature. 2A–F Patient 2 (31-year-
old male), IFN-c/Il-2 mixed signature. 3A–3F Patient 3 (55-year-old
male), IL-2 dominant signature
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isoniazid (INH) treatment against M. tuberculosis. How-
ever, later testing with the Fluorospot assay revealed a
strongly IFN-c dominant signature (Fig. 1, Patient 1;
Fig. 2, 1A–F). This IFN-c dominance might indicate an
ongoing immunological process directed against M.
tuberculosis [8] that supports the need for follow-up
monitoring, particularly considering the untreated status.
The second patient was a 31-year-old female of Kosovar
descent, in good general condition, HCW. The infection was
identified through routine hospital entry screening. The sta-
tus of the BCG vaccination could not be confirmed; however,
an inoculation scar was detected (arm). The clinical history
revealed confirmed close contact with an active TB patient
(within the family) at the age of 16 years. No post-exposure
contact screening or treatment against M. tuberculosis was
recorded, and no TST was performed. No abnormalities were
detected on chest X-ray. Both IGRA tests were clearly
positive: the QFT result was 7.72 IU/ml and the T-SPOT.TB
results were 182 spots for ESAT-6 and 256 spots for CFP-10,
respectively. The Fluorospot assay revealed a mixed IFN-c/
IL-2 signature (Fig. 1, Patient 2; Fig. 2, 2A–F). The patient
received drug treatment against M. tuberculosis (rifampicin
600 mg, once daily for 6 months).
The third patient was a 55-year-old male of Swiss
descent, in good general condition, HCW. The infection
was identified through routine hospital screening. The
status of the BCG vaccination was confirmed. The clinical
history showed repeated potential exposures during several
professional assignments in Eastern Europe over the past
years. No abnormalities were detected on chest radiograph,
and no TST was performed. Both IGRA tests were weak
positive: the QFT result was 0.52 IU/ml and the
T-SPOT.TB results were 10 spots for ESAT-6. The Flu-
orospot assay revealed an IL-2 dominant signature (Fig. 1,
Patient 3; Fig. 2, 3A–F). The patient did not receive pre-
ventive INH therapy against M. tuberculosis.
Discussion
We have shown that clearly distinguishable IFN-c and IL-2
signatures can be obtained in IGRA-positive individuals
using the Fluorospot assay. These IFN-c and IL-2 signa-
tures can be used as an additional criterion by clinicians,
allowing for a personalized risk assessment of IGRA-
positive subjects for which there are no further clinical,
radiological, or anamnestic parameters available. Individ-
uals with IFN-c dominant or mixed signatures whose
immune system might be in the process of actively fighting
M. tuberculosis could bear a higher risk of developing
active disease and therefore be indicated for treatment or
clinical follow-up. Determination of the IFN-c and IL-2
functional signature might also help to further assess the
status of individuals showing increased within-subject
variability (e.g., multiple conversions and reversions in
serial testing), a phenomenon encountered using both the
QFT and the T-SPOT.TB assays [12, 13], as well as indi-
viduals with consistent low positive QFT results (C0.35 to
\1.0 IU/ml), who generally seem to have an overall higher
IL-2/IFN-c ratio when compared to QFT intermediate
responders (1.0–5.0 IU/ml) or QFT strong responders
([5.0 IU/ml) [10]. Additional data are needed to obtain
cut-off values that allow a clear distinction between IFN-c,
IL-2, and IFN-c/IL-2 mixed signatures. Further studies to
determine not only IFN-c and IL-2 activity, but also the
possible role of TNF-a as an additional Fluorospot marker
[14] are warranted.
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